The cytotoxic action of ribonucleases (RNases) requires the interaction of the enzyme with the cellular membrane, its internalization, translocation to the cytosol, and the degradation of ribonucleic acid. The interplay of these processes as well as the role of the thermodynamic and proteolytic stability, the catalytic activity, and the evasion from the intracellular ribonuclease inhibitor (RI) has not yet been fully elucidated. As cytosolic internalization is indispensable for the cytotoxicity of extracellular ribonucleases, we investigated the extent of cytosolic internalization of a cytotoxic, RI-evasive RNase A variant (G88R-RNase A) and of various similarly cytotoxic but RI-sensitive RNase A tandem enzyme variants in comparison to the internalization of the non-cytotoxic and RI-sensitive RNase A. After incubation of K-562 cells with the RNase A variants for 36 h, the internalized amount of RNases was analyzed by rapid cell disruption followed by subcellular fractionation and semiquantitative immunoblotting. The data indicate that an enhanced cellular uptake and an increased entry of the RNases into the cytosol can outweigh the abolishment of catalytic activity by RI. As all RNase A variants proved to be resistant to the proteases present in the different subcellular fractions for more than 100 h, our results suggest that the cytotoxic potency of RNases is determined by an efficient internalization into the cytosol.The ribonucleolytic activity of ribonucleases (RNases) 2 provides the potential to use these enzymes as therapeutics for tumor treatment. Particularly, members of the RNase A and RNase T1 superfamilies have shown promising cytotoxicity to cancer cells (1-3). Among these enzymes, Onconase TM (Alfacell Corp., Bloomfield, NJ), an RNase from the Northern Leopard frog, is farthest along the clinical trials (4). To overcome the disadvantage of the renal toxicity of Onconase and a possible immunogenicity of non-mammalian RNases, RNase A or human pancreatic RNase 1 evolved as targets for the development of antitumor agents (5). Because RNases from mammalian sources are silenced due to the tight binding by the intracellular inhibitor protein (RI) and, thus, are not cytotoxic (6), various strategies have been mapped out to accomplish cytotoxicity. Inspired by the cytotoxicity of the amphibian Onconase (5,7,8) and the dimeric bovine seminal RNase (9), tremendous efforts have been made to create RNase derivatives that evade RI binding. While the generation of chimeras (10 -13), the use of chemical modifications (14 -17), or site-directed mutagenesis (5, 6, 18 -21) proved to be strategies of rather varying success, we developed RNase A tandem enzymes (22) in which two RNase A molecules are coupled covalently by a peptide linker. Due to steric hindrance, a complete binding by RI should be prevented and in contrast to bovine seminal RNase, the RNase A entities of the tandem constructs cannot dissociate, which would result in a subsequent binding by RI. In fact, the RNase A tandem constructs have been found to...